Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Accounting Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,466.9845 |
Reported balance
After 2026-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 27 · Balance 1,466.9845 F1: Includes 98.3178 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2026, 6/30/2026, and 9/30/2026. |
| Common StockSEC Table I · non-derivative | Direct | 1,458.9845 |
Reported balance
After 2026-10-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-10-02 · Tax withholding · Disposed 8 · Balance 1,458.9845 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-10-01 | Direct | 985 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Grant · Acquired 985 · Balance 985 F2: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 1, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2026-10-02 | Direct | 0 |
Reported balance
After 2026-10-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-02 · Exercise / conversion · Disposed 27 · Balance 0 F3: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 2, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 98.3178 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2026, 6/30/2026, and 9/30/2026.
F2: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 1, 2026.
F3: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 2, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 21:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 27 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000084 · form4.xml · derivative · entry 4 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27 shares Expires 2026-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 2, 2023. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 21:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 8 | $219.88 | $1,759.04 |
DisclosureSEC source: 0000875045-26-000084 · form4.xml · nonDerivative · entry 2 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458.9845 Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 21:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000084 · form4.xml · nonDerivative · entry 1 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,466.9845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 98.3178 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2026, 6/30/2026, and 9/30/2026. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 21:00 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 985 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000084 · form4.xml · derivative · entry 3 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 985 Underlying: Common Stock · 985 shares Expires 2029-10-01 F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of October 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000036 · form4.xml · derivative · entry 3 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364 Underlying: Common Stock · 181 shares Expires 2028-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 54 | $183.78 | $9,924.12 |
DisclosureSEC source: 0000875045-26-000036 · form4.xml · nonDerivative · entry 2 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,341.6667 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000036 · form4.xml · nonDerivative · entry 1 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,395.6667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:07 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000027 · form4.xml · derivative · entry 1 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 517 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · derivative · entry 9 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,035 Underlying: Common Stock · 517 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/06/2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 305 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · derivative · entry 8 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305 Underlying: Common Stock · 305 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 257 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · derivative · entry 7 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 180 | $201.18 | $36,212.40 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 6 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,214.6667 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 517 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 5 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,394.6667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 103 | $201.18 | $20,721.54 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 4 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877.6667 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 305 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 3 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 980.6667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 76 | $201.18 | $15,289.68 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 2 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675.6667 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000016 · form4.xml · nonDerivative · entry 1 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751.6667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 17:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 26 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000037 · form4.xml · derivative · entry 3 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27 Underlying: Common Stock · 26 shares Expires 2026-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 10/02/2023. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 17:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 8 | $155.25 | $1,242.00 |
DisclosureSEC source: 0000875045-25-000037 · form4.xml · nonDerivative · entry 2 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494.6667 Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 17:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 26 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000037 · form4.xml · nonDerivative · entry 1 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502.6667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 545 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-011365 · form4.xml · derivative · entry 2 Godbout Sean · CIK 0002057736 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545 Underlying: Common Stock · 545 shares Expires 2028-04-01 F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of April 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.